{
  "1AD.AX": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "AdAlta Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ADALTA FPO",
    "state": "VIC",
    "summary": "AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with GE Healthcare to discover i-bodies against granzyme B for use as a molecular imaging agent. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.",
    "website": "http://adalta.com.au",
    "zipcode": "3083"
  },
  "3AC.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Actinogen Medical Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACTINOGEN MEDICAL LTD.",
    "state": "NSW",
    "summary": "Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.",
    "website": "http://www.actinogen.com.au",
    "zipcode": "2000"
  },
  "51S.F": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cynata Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CYNATA THERAPEUTICS",
    "state": "VIC",
    "summary": "Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",
    "website": "http://www.cynata.com",
    "zipcode": "3053"
  },
  "ACR.AX": {
    "city": "West Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Acrux Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACRUX FPO",
    "state": "VIC",
    "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
    "website": "http://www.acrux.com.au",
    "zipcode": "3003"
  },
  "ACW.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Actinogen Medical Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ACTINOGEN FPO",
    "state": "NSW",
    "summary": "Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.",
    "website": "http://www.actinogen.com.au",
    "zipcode": "2000"
  },
  "ADO.AX": {
    "city": "Eight Mile Plains",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "AnteoTech Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ANTEO TECH FPO",
    "state": "QLD",
    "summary": "AnteoTech Limited engages in developing, commercializing, manufacturing, and distributing products for the life sciences research, vitro diagnostics, energy, and medical device markets primarily in Australia. Its principal technology products include AnteoCoat, which is applicable to the energy sector in lithium-ion batteries; AnteoBind that is applicable to point of care, in vitro, and life science diagnostic sectors. The company also manufactures and sells COVID-19 antigen testing kits. AnteoTech Limited has collaboration agreements with Axxin for for COVID-19 anigen test. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited was incorporated in 1995 and is headquartered in Eight Mile Plains, Australia.",
    "website": "http://www.anteotech.com",
    "zipcode": "4113"
  },
  "ANR.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Anatara Lifesciences Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ANATARA LS FPO",
    "state": "VIC",
    "summary": "Anatara Lifesciences Limited engages in the research and development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans in Australia. Its lead product candidate includes Detach, a non-antibiotic therapy that prevents and treats diarrhea disease in piglets. The company is also developing bromelain formulations for gastrointestinal health in humans, as well as for piglets and poultry. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.",
    "website": "http://www.anataralifesciences.com",
    "zipcode": "3053"
  },
  "ANW.F": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMMURON LTD",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "ANWA.F": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMMURON LTD SPON.ADR 40",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "ARUXF": {
    "city": "West Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Acrux Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACRUX",
    "state": "VIC",
    "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
    "website": "http://www.acrux.com.au",
    "zipcode": "3003"
  },
  "ATH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY FPO",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "ATHE": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Alterity Therapeutics Limited",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "ATX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Amplia Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AMPLIA FPO",
    "state": "VIC",
    "summary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",
    "website": "http://www.ampliatx.com",
    "zipcode": "3000"
  },
  "AVE.AX": {
    "city": "Clayton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Avecho Biotechnology Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AVECHO FPO",
    "state": "VIC",
    "summary": "Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.",
    "website": "http://avecho.com.au",
    "zipcode": "3168"
  },
  "B1N.F": {
    "city": "Thebarton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Bionomics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIONOMICS LTD.",
    "state": "SA",
    "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
    "website": "http://www.bionomics.com.au",
    "zipcode": "5031"
  },
  "BGT.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Bio-Gene Technology Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOGENETEC FPO",
    "state": "VIC",
    "summary": "Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.",
    "website": "http://www.bio-gene.com.au",
    "zipcode": "3000"
  },
  "BIT.AX": {
    "city": "North Ryde",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Biotron Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOTRON FPO",
    "state": "NSW",
    "summary": "Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.",
    "website": "http://www.biotron.com.au",
    "zipcode": "2113"
  },
  "BITRF": {
    "city": "North Ryde",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Biotron Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOTRON",
    "state": "NSW",
    "summary": "Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.",
    "website": "http://www.biotron.com.au",
    "zipcode": "2113"
  },
  "BNO.AX": {
    "city": "Thebarton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Bionomics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIONOMICS FPO",
    "state": "SA",
    "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
    "website": "http://www.bionomics.com.au",
    "zipcode": "5031"
  },
  "BNOEF": {
    "city": "Thebarton",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Bionomics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIONOMICS LTD",
    "state": "SA",
    "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
    "website": "http://www.bionomics.com.au",
    "zipcode": "5031"
  },
  "BOT.AX": {
    "city": "North Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Botanix Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BOTANIX FPO",
    "state": "WA",
    "summary": "Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.",
    "website": "http://www.botanixpharma.com",
    "zipcode": "6006"
  },
  "BTC.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "BTC Health Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BTC HEALTH FPO",
    "state": "VIC",
    "summary": "BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia. The fund invests in both listed and unlisted companies.",
    "website": "http://www.btchealth.com.au/",
    "zipcode": "3124"
  },
  "BXN.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Bioxyne Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOXYNE FPO",
    "state": "NSW",
    "summary": "Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates in two segments, Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and fortified milk formula for nutrition and immune support; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.",
    "website": "http://www.bioxyne.com",
    "zipcode": "2000"
  },
  "BXPHF": {
    "city": "North Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Botanix Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BOTANIX PHARMACEUTICALS LTD",
    "state": "WA",
    "summary": "Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.",
    "website": "http://www.botanixpharma.com",
    "zipcode": "6006"
  },
  "CALZF": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "PolyNovo Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "POLYNOVO LIMITED",
    "state": "VIC",
    "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
    "website": "http://www.polynovo.com.au",
    "zipcode": "3207"
  },
  "CDY.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Cellmid Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CELLMID FPO",
    "state": "NSW",
    "summary": "Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.",
    "website": "http://www.cellmid.com.au",
    "zipcode": "2000"
  },
  "CHM.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Chimeric Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CHIMERIC FPO",
    "state": "VIC",
    "summary": "Chimeric Therapeutics Limited, a biotechnology company, develops and commercializes chimeric antigen receptor T cell therapy drugs for solid tumors in Australia. It is developing CLTX-CAR T cell therapy that is Phase I clinical study in Glioblastoma. The company was incorporated in 2020 and is based in Carlton, Australia.",
    "website": "http://www.chimerictherapeutics.com",
    "zipcode": "3053"
  },
  "CLVLF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "CLVLY": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "CMXHF": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSJ.F": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSJA.F": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD  SPON.ADR 2",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSL.AX": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "au_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL FPO",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSLLY": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSLN.MX": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CUV.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL FPO",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "CYP.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Cynata Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CYNATA THR FPO",
    "state": "VIC",
    "summary": "Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",
    "website": "http://www.cynata.com",
    "zipcode": "3053"
  },
  "DXB.AX": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Dimerix Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DIMERIX FPO",
    "state": "VIC",
    "summary": "Dimerix Limited, a biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. It offers DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis; and DMX-700, which is in pre-clinical stage for the treatment of chronic obstructive pulmonary disease, as well as proprietary ReceptorHIT assay technology. The company was incorporated in 1975 and is headquartered in Fitzroy, Australia.",
    "website": "http://dimerix.com",
    "zipcode": "3065"
  },
  "E4N.F": {
    "city": "Osborne Park",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Suda Pharmaceuticals Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SUDA PHARMACEUTICALS LTD.",
    "state": "WA",
    "summary": "Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.",
    "website": "http://sudapharma.com",
    "zipcode": "6017"
  },
  "ECQ.F": {
    "city": "Bentley",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "PharmAust Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAUST LTD.",
    "state": "WA",
    "summary": "PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.",
    "website": "http://www.pharmaust.com",
    "zipcode": "6102"
  },
  "EX1.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Exopharm Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EXOPHARM FPO",
    "state": "VIC",
    "summary": "Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing NaÃ¯ve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.",
    "website": "http://www.exopharm.com",
    "zipcode": "3000"
  },
  "FJY.F": {
    "city": "West Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Acrux Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACRUX LTD.",
    "state": "VIC",
    "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
    "website": "http://www.acrux.com.au",
    "zipcode": "3003"
  },
  "G1G.F": {
    "city": "Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Zelira Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZELIRA THERAPEUTICS LTD.",
    "state": "WA",
    "summary": "Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.",
    "website": "http://www.zeliratx.com",
    "zipcode": "6000"
  },
  "HXL.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Hexima Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HEXIMA FPO",
    "state": "VIC",
    "summary": "Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is HXP124, which is in a phase IIb clinical trial for the treatment of fungal toenail infections. It operates in the topical antifungal sector of the pharmaceutical product development industry worldwide. The company was founded in 1997 and is headquartered in Melbourne, Australia.",
    "website": "http://www.hexima.com.au",
    "zipcode": "3086"
  },
  "IG7.F": {
    "city": "Homebush",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Memphasys Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEMPHASYS LTD",
    "state": "NSW",
    "summary": "Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.",
    "website": "http://www.memphasys.com",
    "zipcode": "2140"
  },
  "ILA.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Island Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ISLAND PHA FPO",
    "state": "VIC",
    "summary": "Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug with safety profile for the prevention and treatment of dengue fever and other mosquito borne diseases. The company was founded in 2017 and is based in Camberwell, Australia.",
    "website": "http://www.islandpharmaceuticals.com",
    "zipcode": "3124"
  },
  "IMC.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMMURON FPO",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "IMM.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP FPO",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "IMMP": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Immutep Limited",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "IMRN": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Immuron Limited",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "IMU.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Imugene Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IMUGENE FPO",
    "state": "NSW",
    "summary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",
    "website": "http://www.imugene.com",
    "zipcode": "2000"
  },
  "INNMF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Amplia Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AMPLIA THERAPEUTICS LTD",
    "state": "VIC",
    "summary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",
    "website": "http://www.ampliatx.com",
    "zipcode": "3000"
  },
  "IUGNF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Imugene Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IMUGENE LIMITED",
    "state": "NSW",
    "summary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",
    "website": "http://www.imugene.com",
    "zipcode": "2000"
  },
  "IXC.AX": {
    "city": "Subiaco",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Invex Therapeutics Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INVEX THER FPO",
    "state": "WA",
    "summary": "Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.",
    "website": "http://www.invextherapeutics.com",
    "zipcode": "6008"
  },
  "KZA.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAZIA FPO",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "KZIA": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Kazia Therapeutics Limited",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "LCT.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIV CELL FPO",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LHI.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVING CELL TECHS",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LVCLF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVING CELL TECHNOLOGIES",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LVCLY": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVING CELL TECHNOLOGIES",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LWB.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST LTD.",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrÃ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "LWBA.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST SP.ADRS 144A/5",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrÃ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MDC.AX": {
    "city": "Alexandria",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Medlab Clinical Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDLAB FPO",
    "state": "NSW",
    "summary": "Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.",
    "website": "http://www.medlab.co",
    "zipcode": "2015"
  },
  "MEM.AX": {
    "city": "Homebush",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Memphasys Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEMPHASYS FPO",
    "state": "NSW",
    "summary": "Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.",
    "website": "http://www.memphasys.com",
    "zipcode": "2140"
  },
  "MEOBF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST LTD",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrÃ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MESO": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Mesoblast Limited",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrÃ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MFJ.F": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "PolyNovo Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "POLYNOVO LTD",
    "state": "VIC",
    "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
    "website": "http://www.polynovo.com.au",
    "zipcode": "3207"
  },
  "MIGI": {
    "city": "North Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Mawson Infrastructure Group Inc.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MAWSON INFRASTRUCTURE GROUP INC",
    "state": "NSW",
    "summary": "Cosmos Capital Limited, a digital asset infrastructure company, develops and deploys solutions to provide the space and capacity required for businesses, governments, organizations, and individuals to process transactions on distributed networks. The company was incorporated in 2019 and is based in North Sydney, Australia.",
    "website": "http://cosmoscapital.io",
    "zipcode": "2060"
  },
  "MLPH": {
    "city": "Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Molecular Pharmacology (USA), Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MOLECULAR PHARMACOLOGY LIMITED",
    "state": "WA",
    "summary": "Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.",
    "website": null,
    "zipcode": "6007"
  },
  "MSB.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST FPO",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrÃ¼nenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "NC6.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Nanollose Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NANOLLOSE FPO",
    "state": "WA",
    "summary": "Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre. The company's products are used in textiles, nonwoven fabric, and other industries. Nanollose Limited was founded in 2014 and is based in Nedlands, Australia.",
    "website": "http://www.nanollose.com",
    "zipcode": "6009"
  },
  "NEU.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Neuren Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEUREN FPO NZ",
    "state": "VIC",
    "summary": "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.",
    "website": "http://www.neurenpharma.com",
    "zipcode": "3124"
  },
  "NOX.AX": {
    "city": "Gordon",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Noxopharm Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NOXOPHARM FPO",
    "state": "NSW",
    "summary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
    "website": "http://www.noxopharm.com",
    "zipcode": "2072"
  },
  "NOXOF": {
    "city": "Gordon",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Noxopharm Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NOXOPHARM LTD",
    "state": "NSW",
    "summary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
    "website": "http://www.noxopharm.com",
    "zipcode": "2072"
  },
  "NSB.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "NeuroScientific Biopharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NEUROSCIEN FPO",
    "state": "WA",
    "summary": "NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.",
    "website": "http://www.neuroscientific.com",
    "zipcode": "6009"
  },
  "NURPF": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Neuren Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEUREN PHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.",
    "website": "http://www.neurenpharma.com",
    "zipcode": "3124"
  },
  "NV9.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAZIA THERAPEUTICS",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "NV9M.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAZIA THER.LTD.ADR 10 NEW",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "NYR.AX": {
    "city": "Gordon",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Nyrada Inc.",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NYRADA CDI FORUS",
    "state": "NSW",
    "summary": "Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. Nyrada Inc. has collaboration with Walter Reed Army Institute of Research and UNSW. The company was founded in 2017 and is based in Gordon, Australia.",
    "website": "http://www.nyrada.com",
    "zipcode": "2072"
  },
  "OCC.AX": {
    "city": "Murdoch",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Orthocell Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORTHOCELL FPO",
    "state": "WA",
    "summary": "Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.",
    "website": "http://www.orthocell.com.au",
    "zipcode": "6150"
  },
  "OEZ.F": {
    "city": "Clayton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Avecho Biotechnology Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AVECHO BIOTECHN. LTD",
    "state": "VIC",
    "summary": "Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.",
    "website": "http://avecho.com.au",
    "zipcode": "3168"
  },
  "OPT": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Opthea Limited",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "OPT.AX": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "OPTHEA FPO",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "PAA.AX": {
    "city": "Bentley",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "PharmAust Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAUST FPO",
    "state": "WA",
    "summary": "PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.",
    "website": "http://www.pharmaust.com",
    "zipcode": "6102"
  },
  "PAB.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Patrys Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PATRYS FPO",
    "state": "VIC",
    "summary": "Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.",
    "website": "http://www.patrys.com",
    "zipcode": "3205"
  },
  "PAR.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Paradigm Biopharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PARA BIO FPO",
    "state": "VIC",
    "summary": "Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.",
    "website": "http://www.paradigmbiopharma.com",
    "zipcode": "3000"
  },
  "PBIGF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Paradigm Biopharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PARADIGM BIOPHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.",
    "website": "http://www.paradigmbiopharma.com",
    "zipcode": "3000"
  },
  "PBN.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY THERAPEUT. LTD",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "PBNN.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY THERAPEUT.ADR/60",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "PH7.F": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "PYC Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PYC THERAPEUTICS LTD.",
    "state": "WA",
    "summary": "PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.",
    "website": "http://pyctx.com",
    "zipcode": "6009"
  },
  "PH7.SG": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "PYC Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Phylogica Ltd. Registered Share",
    "state": "WA",
    "summary": "PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.",
    "website": "http://pyctx.com",
    "zipcode": "6009"
  },
  "PIQ.AX": {
    "city": "Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Proteomics International Laboratories Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PROTEOMICS FPO",
    "state": "WA",
    "summary": "Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma, the primary common form of oesophageal cancer in Australia. The company was founded in 2001 and is based in Perth, Australia.",
    "website": "http://www.proteomics.com.au",
    "zipcode": "6009"
  },
  "PNV.AX": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "PolyNovo Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "POLYNOVO FPO",
    "state": "VIC",
    "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
    "website": "http://www.polynovo.com.au",
    "zipcode": "3207"
  },
  "PPCB": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Propanc Biopharma, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PROPANC BIOPHARMA INC",
    "state": "VIC",
    "summary": "Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of JaÃ©n to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.",
    "website": "http://www.propanc.com",
    "zipcode": "3124"
  },
  "PQ6.F": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA HOLDINGS LTD.",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "PRNAF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY THERAPEUTICS LIMITED",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "PRRUF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP LTD",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "PTX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Prescient Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PRESCIENT FPO",
    "state": "VIC",
    "summary": "Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.",
    "website": "http://ptxtherapeutics.com",
    "zipcode": "3205"
  },
  "PYC.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "PYC Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PYC THERAP FPO",
    "state": "WA",
    "summary": "PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.",
    "website": "http://pyctx.com",
    "zipcode": "6009"
  },
  "R9Q.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Recce Pharmaceuticals Ltd",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RECCE PHARMACEUTICALS LTD",
    "state": "NSW",
    "summary": "Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.",
    "website": "http://www.recce.com.au",
    "zipcode": "2000"
  },
  "RAC.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Race Oncology Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RACEONCO FPO",
    "state": "NSW",
    "summary": "Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The company is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. It has a preclinical research program with the University of Newcastle to explore the use of Bisantrene to treat melanoma. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.",
    "website": "http://www.raceoncology.com",
    "zipcode": "2000"
  },
  "RAONF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Race Oncology Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RACE ONCOLOGY LTD",
    "state": "NSW",
    "summary": "Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The company is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. It has a preclinical research program with the University of Newcastle to explore the use of Bisantrene to treat melanoma. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.",
    "website": "http://www.raceoncology.com",
    "zipcode": "2000"
  },
  "RCE.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Recce Pharmaceuticals Ltd",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RECCE LTD FPO",
    "state": "NSW",
    "summary": "Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.",
    "website": "http://www.recce.com.au",
    "zipcode": "2000"
  },
  "RGS.AX": {
    "city": "Paddington",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Regeneus Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "REGENEUS FPO",
    "state": "NSW",
    "summary": "Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.",
    "website": "http://regeneus.com.au",
    "zipcode": "2021"
  },
  "SPHRF": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA HOLDINGS LIMITED",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "SPHRY": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA HOLDINGS LIMITED",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "SPL.AX": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA FPO",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "SUD.AX": {
    "city": "Osborne Park",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Suda Pharmaceuticals Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SUDA FPO",
    "state": "WA",
    "summary": "Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.",
    "website": "http://sudapharma.com",
    "zipcode": "6017"
  },
  "TLPPF": {
    "city": "North Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Telix Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TELIX PHARMACEUTIC",
    "state": "VIC",
    "summary": "Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.",
    "website": "http://www.telixpharma.com",
    "zipcode": "3051"
  },
  "TLX.AX": {
    "city": "North Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Telix Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TELIXPHARM FPO",
    "state": "VIC",
    "summary": "Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.",
    "website": "http://www.telixpharma.com",
    "zipcode": "3051"
  },
  "UKJ.F": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "OPTHEA LTD",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "UKJ2.F": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "OPTHEA LTD (SP.ADR/8)",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "UR9.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMACEUTICALS",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "UR9A.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMAC.ADRS1",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "VBS.AX": {
    "city": "Rosebery",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Vectus Biosystems Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "VECTUS BIO FPO",
    "state": "NSW",
    "summary": "Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.",
    "website": "http://www.vectusbiosystems.com.au",
    "zipcode": "2018"
  },
  "YP1A.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP LTD ADRS II/10",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "YP1B.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP LTD",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Âeftilagimod alpha' or Âefti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "ZLD.AX": {
    "city": "Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Zelira Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZELIRATHER FPO",
    "state": "WA",
    "summary": "Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.",
    "website": "http://www.zeliratx.com",
    "zipcode": "6000"
  },
  "ZLDAF": {
    "city": "Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Zelira Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZELIRA THERAPEUTICS LTD",
    "state": "WA",
    "summary": "Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.",
    "website": "http://www.zeliratx.com",
    "zipcode": "6000"
  }
}
